Recent Results with Liposomes as Boron Delivery Vehicles for Boron Neutron Capture Therapy

  • M. Frederick Hawthorne
  • Debra A. Feakes
  • Kenneth Shelly


The slow evolution of effective drug-targeting methodologies for the selective delivery of boron to cancer cells persists as an important obstacle to the development of boron neutron capture therapy.1 Simple boron compounds offer the convenience of availability and ease of synthesis but often exhibit low selectivity and require large injected doses in order to produce the required boron concentrations in tumor. The development of new boron compounds with natural tumor selectivity is problematic. The conjugation of boron-rich moieties to existing tumor-selective substrates often leads to problems with loss of tumor specificity, water solubility, and toxicity.


Boron Neutron Capture Therapy Boron Compound Aqueous Core Tumor Retention Liposomal Delivery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. I. M.F. Hawthorne, The role of chemistry in the development of boron neutron capture therapy, Angew.. Chem. Int. Ed. Eng. 32: 950–984, 1993.CrossRefGoogle Scholar
  2. 2.
    K. Shelly, M.F. Hawthorne, and P.G. Schmidt, Liposomal delivery of boron for BNCT, in: “Progress in Neutron Capture Therapy for Cancer;” B.J. Allen, et al., ed., Plenum Press, New York, 1992, pp. 259–264.CrossRefGoogle Scholar
  3. 3.
    D.A. Feakes, K. Shelly, M.F. Hawthorne, P.G. Schmidt, C.A. Elstad, G.G. Meadows, and W.F. Bauer, Liposomal delivery of boron to tumors for boron neutron capture therapy, in: “Advances in Neutron Capture Therapy,” A.H. Soloway, et al., ed.. Plenum Press, New York, 1993, pp. 395–398.CrossRefGoogle Scholar
  4. 4.
    M.F. Hawthorne and R.L. Pilling, Bis(triethylammonium) decahydrodecaborate(2-), Inorg.Srnth. 9: 16–19, 1967.CrossRefGoogle Scholar
  5. 5.
    K. Shelly, C.B. Knobler, and M.F. Hawthorne, Synthesis of monosubstituted derivatives of X-ray crystal structures of [dosa-2-B 10 H 9 CO]’ and ldoso-2-Bi5H,NCO]2-, Inorg. Chem. 31: 2889–2892, 1992.CrossRefGoogle Scholar
  6. 6.
    D.A. Johnson, D.D. Seimer, and W.F. Bauer, Determination of nanogram levels of boron in milligram-sized samples by inductively coupled plasma-atomic emission spectroscopy, Anal. (’him. Acta. 270: 223–230, 1992.Google Scholar
  7. 7.
    B.L. Chamberland and E.L. Muetterties, Chemistry of Boranes. XVIII. Oxidation of [B10H15]2- and its derivatives, lnorg. Chem. 3: 1450–1458, 1964.Google Scholar
  8. 8.
    M.F. Hawthorne, R.L. Pilling, and P.M. Garrett, A study of the reaction of hydroxide ion with B25H J. Am. Chem. Soc. 87: 4740–4746, 1965.CrossRefGoogle Scholar
  9. 9.
    K. Shelly, D.A. Feakes, M.F. Hawthorne, P.G. Schmidt, T.A. Krisch, and W.F. Bauer, Model studies directed toward the neutron capture therapy of cancer: boron delivery to murine tumors with liposomes, Pro’ Natl. Acad. Sci. USA 89: 9039–9043, 1992.CrossRefGoogle Scholar
  10. 10.
    D.A. Feakes, K. Shelly, C.B. Knobler, and M.F. Hawthorne, Na3[B,5Hi7NH3]: synthesis and liposomal delivery to murine tumors, Proc. Natl. Acad. Sci. USA 91: 3029–3033, 1994.PubMedCrossRefGoogle Scholar
  11. 11.
    D.A. Feakes, K. Shelly, and M.F. Hawthorne, Selective boron delivery to murine tumors by lipophilic species incorporated in the membranes of unilamellar liposomes, Proc. Natl. Acad. Sci. USA,in press.Google Scholar
  12. 12.
    D. Lasic, Liposomes, Am. Sci. 80: 20–31, 1992.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • M. Frederick Hawthorne
    • 1
  • Debra A. Feakes
    • 2
    • 1
  • Kenneth Shelly
    • 1
  1. 1.Department of Chemistry and BiochemistryUniversity of California at Los AngelesLos AngelesUSA
  2. 2.Department of ChemistrySouthwest Texas State UniversitySan MarcosUSA

Personalised recommendations